DVLA.JK(DVLA.JK)
DVLA.JK
PT Darya-Varia Laboratoria Tbk is a leading Indonesian pharmaceutical company specializing in both generic and specialty drugs. The company has a strong competitive position in the Southeast Asian market, driven by its diversified product portfolio and established distribution channels across Indonesia.
Darya-Varia generates revenue primarily through the sale of prescription medications, leveraging its strong relationships with healthcare providers and pharmacies. The company benefits from pricing power due to its established brand reputation and regulatory approvals for its products.
Changes in regulatory approvals for new drugs
Market share gains in the Indonesian pharmaceutical sector
Fluctuations in raw material costs impacting gross margins
Expansion into new Southeast Asian markets
Regulatory changes impacting drug approval processes
Technological disruption in drug manufacturing
Increased competition from local and international generic drug manufacturers
Pricing pressure from government regulations on drug pricing
Potential liquidity risks if cash flow declines significantly
Dependence on cash flow for funding R&D initiatives
moderate - the pharmaceutical industry is somewhat insulated from economic downturns, but consumer spending on healthcare can be affected by GDP fluctuations.
Low - as the company operates with zero debt, rising interest rates do not significantly impact financing costs, but could affect consumer spending on healthcare products.
minimal - the company's lack of debt means it is not heavily reliant on credit conditions.
value - the company’s strong fundamentals and low valuation multiples attract value-oriented investors.
low - historically stable earnings and a lack of debt contribute to lower volatility.